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Migraine day frequency in migraine
prevention: longitudinal modelling
approaches
Gian Luca Di Tanna1* , Joshua K. Porter1, Richard B. Lipton2, Alan Brennan3, Stephen Palmer4,
Anthony J. Hatswell5, Sandhya Sapra6 and Guillermo Villa1
Abstract
Background: Health economic models are critical tools to inform reimbursement agencies on health care
interventions. Many clinical trials report outcomes using the frequency of an event over a set period of time,
for example, the primary efficacy outcome in most clinical trials of migraine prevention is mean change in
the frequency of migraine days (MDs) per 28 days (monthly MDs [MMD]) relative to baseline for active
treatment versus placebo. Using these cohort-level endpoints in economic models, accounting for variation
among patients is challenging. In this analysis, parametric models of change in MMD for migraine preventives
were assessed using data from erenumab clinical studies.
Methods: MMD observations from the double-blind phases of two studies of erenumab were used: one in
episodic migraine (EM) (NCT02456740) and one in chronic migraine (CM) (NCT02066415). For each trial, two
longitudinal regression models were fitted: negative binomial and beta binomial. For a thorough comparison
we also present the fitting from the standard multilevel Poisson and the zero inflated negative binomial.
Results: Using the erenumab study data, both the negative binomial and beta-binomial models provided
unbiased estimates relative to observed trial data with well-fitting distribution at various time points.
Conclusions: This proposed methodology, which has not been previously applied in migraine, has shown that these
models may be suitable for estimating MMD frequency. Modelling MMD using negative binomial and beta-binomial
distributions can be advantageous because these models can capture intra- and inter-patient variability so that trial
observations can be modelled parametrically for the purposes of economic evaluation of migraine prevention. Such
models have implications for use in a wide range of disease areas when assessing repeated measured utility values.
Keywords: Erenumab, Migraine, Migraine frequency, Modelling, Negative binomial, Beta-binomial
Background
Migraine is a common neurological disorder charac-
terised by debilitating, recurrent headaches, often di-
vided into episodic (EM) and chronic (CM) forms based
on month headache days (MHD) and monthly migraine
days (MMD) (EM, 4–14 MMD and < 15 MHD, or CM,
≥15 MHD and ≥ 8 MMD) [1–3]. Migraine pain is typic-
ally unilateral, pulsating in quality, of moderate or severe
intensity and aggravated by routine physical activity,
such as walking or climbing stairs. In addition, diagnosis
depends on the presence of associated symptoms of nau-
sea, vomiting, photophobia or phonophobia in various
combinations [1, 2, 4]. The burden of migraine is con-
siderable, both in terms of the physical and emotional
effects on the individual, and the economic impact of
lost productivity and healthcare resource use [5]. It is
ranked as the leading cause of neurological disability
worldwide and is one of the five leading causes of
long-term disability [6, 7].
Preventive treatment intended to reduce the frequency
and severity of headaches is an important aspect of man-
agement; all patients with CM would benefit from
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preventative treatment. Among patients with EM, ex-
periencing 4 or more headache days per month is a lead-
ing reason for considering preventative therapy [8].
MMD and MHD are counts that have values that in-
clude zero as well as positive integers; count data typic-
ally have skewed distributions [9]. Reductions in the
frequencies of migraine days (MDs) and headache days
are key measures of the efficacy of migraine prophylaxis.
Clinical studies typically examine the mean change in
MMD frequency; patient-level data are not widely pub-
lished. However, examining the mean change in MMD
frequency across a cohort of patients may not capture
the clinically meaningful effects of migraine prevention,
such as the improvement in an individual’s ability to per-
form daily activities or health-related quality of life. Fur-
thermore, examining the mean change in the MMD
frequency for a population in clinical studies may not be
applicable in the real-world, as treatments may shift the
frequency distribution.
A higher frequency of MMD per 28 days is associated
with lower health-related quality of life, increased use of
medical resources, acute medication use and increased
productivity losses, with the impact of each additional
MD increasing with overall frequency. As such, the aver-
age outcomes across a patient cohort may not be the
same as the outcomes of a patient with the average
MMD frequency. The frequency distribution of MHD
and MMD is important when it comes to modelling the
effectiveness and cost-effectiveness of prophylaxis [10].
Previous analyses examining cost-effectiveness models
for migraine have approached this issue by defining
health states as categorical event frequency (transition
from ≥15 MHD to < 15 MHD) or as response status
(≥50% reduction in MHD) [10–13] which may not ad-
equately account for inter-patient variability. These
models group together a heterogeneous set of patient
outcomes, rendering the models less precise; for ex-
ample Markov models tend to categorise patients into
broad categories, which can be challenging when asses-
sing benefits. In general, categorising count/continuous
variables can lead to several problems including loss of
information and may also increase the risk of false posi-
tives [14]. Furthermore, use of a data-derived ‘optimal’
cutpoint may lead to bias [15]. Migraine is a disease with
considerable variability in the frequency, duration and
severity of migraine attacks [16]. Therefore, there is a
need for an approach that estimates the change in mean
frequency of MMD but also the distribution of individ-
ual patients by MMD frequency within a cohort at sub-
sequent time points.
Selection of the most appropriate model is important
when fitting MHD or MMD data [17]. There are several
approaches to modelling these data. Reports on model-
ling MMD frequency in the literature are limited but
previous analyses have used Poisson and negative bino-
mial to model headache day frequency [17–21].
Zero-inflated variants of these distributions have also
been used to improve goodness-of-fit [17, 22]. The Pois-
son distribution belongs to the family of discrete prob-
ability distributions traditionally used to model count
data. In general, the model assumes that the mean and
variance of the count data are equal [23]. It is considered
appropriate for unrestricted count data [24], and because
MMD frequency is a count variable, Poisson distribution
may be considered an eligible model. However, its ability
to model the variation seen in the patient-level data has
proved limited [20, 25] due to insufficient accounting for
overdispersion (where a single parameter is insufficient to
characterise the mean and variance) [26]. More recently,
thanks to Shmueli et al. there has been a resurgence in
interest in Conway-Maxwell-Poisson distributions, origin-
ally proposed by Conway and Maxwell to handle queuing
systems [27, 28]. The main characteristic of these distribu-
tions, which are an extension of the Poisson distribution,
is the ability to handle both overdispersion and underdis-
persion. These distributions are limited, however, due to
the lack of a hierarchical model to assess repeated mea-
surements and parameterization that is not made directly
via the mean of counts, making these distributions not
easily comparable to other count regression models. By
contrast, the negative binomial distribution, which uses an
additional dispersion parameter to represent the add-
itional variation seen in the data, has provided superior fits
when modelling migraine populations [17, 20].
A preliminary analysis, based on cross-sections of the
data, has indicated that the beta-binomial is an alterna-
tive distribution that could be used to model MMD
frequency data and has been shown to provide compar-
able fits to the negative binomial models [25]. The
beta-binomial model is commonly used to account for
intraclass correlation coefficients (ICC) among dichot-
omous outcomes in cluster sampling [29]. The use of
the beta-binomial model may offer some advantages be-
cause the outcome can be restricted to a maximum
number of possible successes (i.e. a maximum of 28
MMD per 4-week period).
In order to assess the feasibility of fitting MMD data
using negative binomial or beta-binomial models, longi-
tudinal data from two erenumab studies were examined
[30, 31]. Erenumab is a fully human monoclonal anti-
body that specifically binds to and blocks the calcitonin
gene-related peptide (CGRP) receptor [32]. Erenumab
has been evaluated as a prophylactic treatment for mi-
graine in 2 pivotal clinical trials in patients with EM and
CM [30, 31, 33].
To the best of our knowledge, longitudinal negative bi-
nomial and beta-binomial regression models that accom-
modate over-dispersed data have not been used previously
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in the assessment of MMD frequency. Here, we describe
an assessment of these models of the change in MMD fre-
quency, using data from the placebo and erenumab 140
mg arms of two pivotal erenumab clinical trials.
Methods
Models specification
Three longitudinal regression models were evaluated for
their ability to estimate the frequency distribution of
MMD: multilevel/hierarchical negative binomial regres-
sion (with constant dispersion parameter over time),
multilevel beta-binomial regression (with constant ICC
over time) and the multilevel Poisson model. The distri-
butions in the erenumab cohorts of the studies were es-
timated and compared to the observed distribution
across the double-blind period. Zero-inflated negative bi-
nomial models with robust standard errors clustering at
patient level (presented in Additional file 1: Table S1 and
Additional file 2: Figure S1) were also fitted, but only the
non-zero-inflated were considered here because
zero-inflated models did not improve the model’s fit,
and there was no substantial inflation of zeros due to
the eligibility criteria for the study [20].
Negative binomial distribution
The negative binomial distribution is an extension of the
Poisson distribution and includes a dispersion parameter
(τ) to account for overdispersion in the data. The nega-
tive binomial does not have an upper bound (unlike the
beta binomial), so it is possible for high mean frequen-
cies to result in predictions above the maximum of 28
MDs per month. The dispersion parameter is estimated
based on the mean MD frequency.
The negative binomial probability function [34] is de-
fined as:
P Y ¼ kð Þ ¼
T k þ τð Þ
k!T τð Þ
τ
τþ λ
 τ
λ
λþ τ
 k
k ¼ 0; 1; 2;…
ð1Þ
Where:
 P(Y = k) is the probability of a patient experiencing k
MDs per 28 days
 λ is the mean MDs per 28 days
 τ is the dispersion parameter.
Note that the dispersion parameter estimated by Stata
is 1 divided by the dispersion parameter in eq. 1. To en-
sure that the function sums to unity, the model divides
each estimated frequency by the cumulative frequency of
the negative binomial at Y = 28 (28 MDs per 28 days).
This regression framework can accommodate differ-
ences in MMD frequency and the variation in frequency
between patients at different time points. Parameters
that accommodate overdispersion were estimated for the
negative binomial regression, referred to as the disper-
sion parameter.
Beta-binomial distribution
The beta-binomial data model is a combined model of
the beta and binomial distributions. It is used to model
the number of successes (counts) over a number of bi-
nomial trials, when the probability of success is a beta
distribution with two specific parameters (α and β)
[35]. In general, the beta-binomial distribution accounts
for the fact that the observed events are not equally dis-
tributed across patients and can be used to assess
non-linear associations [35]. In the beta-binomial distri-
bution, the count data at each observation timepoint
are regarded as a set of 28 binary outcomes (MD or
non-MD) grouped by patient. The α and β parameters
of the beta-binomial distribution can be calculated from
the mean and ICC, which represents the strength of the
correlation between days for the same patient, i.e. daily
outcomes are likely to be similar for the same patient.
The beta-binomial probability function is specified as
follows:
PðY ¼ kÞ ¼ ð
N
k
Þ
Bðαþ k; βþ N-kÞ
Bðα; βÞ
k ¼ 0; 1; 2;…
ð2Þ
Where:
 k is the number of MDs
 P (Y = k) is the probability of patients experiencing τ
MDs
 N is the number of days in the cycle (28 days)
 B () is the beta function
 α and β are the parameters of the underlying beta
distribution.
The ICC is assumed constant over time and equal to 1
/ (1 + α + β).
Erenumab clinical trial data
Table 1 summarises some of the key characteristics of the
patients from the two erenumab studies. The patient data
used in the modelling analysis were taken from two piv-
otal clinical trials of erenumab as migraine prophylaxis;
one in patients with EM (NCT02456740) [30], the other
in patients with CM (NCT02066415) [31]. Patients en-
rolled in the EM study had 4 to 14 MDs and fewer than
15 headache days per month (28 days) at baseline. Patients
in the CM study had 15 or more headache days per month
at baseline, of which at least 8 were MDs. Both of these
randomised, double-blind studies compared erenumab 70
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mg and 140mg, administered every 28 days by subcutane-
ous injection, with placebo [30, 31]. Patients received
double-blind treatment for 12 weeks (CM study) or 24
weeks (EM study), and efficacy was assessed as the change
in mean MMD from baseline. This analysis focuses on the
erenumab 140mg dose only. Patient-level data were ob-
tained for the patients in each study, with the following
variables extracted for use in the analysis: subject ID,
MMD frequency, visit, and treatment. This approach al-
lows the regression models to estimate both the change in
MMD frequency over time and the dispersion parameters
required to reproduce the distribution of patient-level
MMD frequency.
Goodness of fit of the regression models was assessed
by estimating the root mean squared errors (RMSE)
across the estimated values compared with trial observa-
tions, mean absolute errors (MAE) and visual inspection
of the predicted distributions. The models could not be
compared via Akaike’s information criteria (AIC) or
Bayesian information criterion (BIC) because the
beta-binomial model was performed on the augmented
dataset.
Predicted MMD values and 95% confidence intervals
were calculated with the Delta method. For economic
modelling purposes, the mean MMD frequencies were
extrapolated beyond the trial observation, up to a max-
imum of 2 years, after which no further change in MMD
frequency was assumed. The models tested were expo-
nential, logistic, log-logistic and Gompertz. Extrapolation
was performed using a logistic function, the best-fitting
function out of the models tested. Further information
on the extrapolations can be found in the supplementary
material (Additional file 3: Figure S2).
All analyses were performed using Stata Statistical
Software: Release 15.0 (StataCorp LLC, College Station,
TX, USA) [36], and the Stata codes to fit the regression
models proposed are located in the Additional file 4:
Technical appendix.
Results
Patient characteristics
Baseline patient characteristics were similar in the two
studies, despite differences in MMD frequency at base-
line (patients experienced an average of 8 vs 18 MDs per
28 days for EM and CM respectively) (Table 1). In the
EM study, mean age was 40.9 years, and the majority of
patients were white (89.1%) and female (85.2%). In the
CM study, these figures were similar with a mean age of
42.5 years, 94.2% were white and 82.8% were female.
MMD frequency modelling
Figure 1 shows the predicted distributions of patients in
the two cohorts compared with the study observations
at weeks 0, 4, 12 and 24 in the EM study. In the EM
study, the predicted distributions for both regression
models show a good fit with the actual data at 4, 12
and 24 weeks (Fig. 1). Figure 2 shows the predicted
distributions and actual data at weeks 0, 4, 8 and 12 in
the CM study. The predicted distributions show a
good fit to the actual observations in the EM and CM
study; the RMSE estimates were 0.075 and 0.082 for
negative binomial regression, 0.102 and 0.081 for
beta-binomial regression and 0.142 and 0.152 for Pois-
son regression for EM and CM studies respectively.
The MAE estimates were 0.246 and 0.330 for negative
binomial regression, 0.336 and 0.339 for beta-binomial
regression, and 0.466 and 0.654 for Poisson regression
for EM and CM studies respectively. For negative bi-
nomial regression, the dispersion parameter was
0.2397 for the EM study and 0.1323 for the CM study;
for the beta-binomial regression, the ICC values were
Table 1 Baseline characteristics of patients in the erenumab clinical trials [31, 43]
Characteristic Episodic migrainea (NCT02456740) Chronic migraineb (NCT02066415)
Group Placebo Erenumab 140mg Placebo Erenumab 140mg
Number of patients 319 319 286 190
Mean age (SD) 41.3 (11.2) 40.4 (11.1) 42.1 (11.3) 42.9 (11.1)
Sex, n (%)
Male 45 (14.1) 47 (14.7) 60 (21.0) 30 (15.8)
Female 274 (85.9) 272 (85.3) 226 (79.0) 160 (84.2)
Race, n (%)
White 277 (86.8) 293 (91.8) 268 (93.7) 184 (96.8)
Black 24 (7.5) 18 (5.6) 11 (3.8) 6 (3.2)
Other 18 (5.6) 8 (2.5) 7 (2.4) 0 (0.0)
Baseline MMD 8.2 (± 2.5) 8.3 (± 2.5) 18.2 (± 4.7) 17.8 (± 4.7)
n number, MMD monthly migraine days, SD standard deviation
aDefined as patients experiencing 4–14 headache days per 28 days, 4–14 migraine days per 28 days
bDefined as patients experiencing ≥15 headache days per 28 days, ≥8 migraine days per 28 days
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0.0297 and 0.1370 for the EM and CM studies (Ta-
bles 2 and 3).
For the EM study, the negative binomial mean MMD
for weeks 0, 4, 12 and 24 were 8.261, 7.199, 6.434 and
6.421, respectively. For beta-binomial regression, the
mean MMD for weeks 0, 4, 12 and 24 were 7.945, 7.080,
6.386 and 6.293, respectively (Table 2). For the CM
study, the negative binomial mean MMD for weeks 0, 4,
8 and 12 were 18.111, 15.418, 14.538 and 13.997, re-
spectively. For beta-binomial regression the mean MMD
for weeks 0, 4, 8 and 12 were 17.111, 15.843, 15.256 and
14.894, respectively (Table 3).
The predicted distributions observed in the CM
study appeared a less close fit than for the EM study,
which reflects the greater level of variability in the
data from the CM study. Figure 3 presents the mean
MMD frequencies for placebo predicted by the nega-
tive binomial and beta-binomial regression models
compared with the observed mean values from pa-
tients with EM over the 24-week study period. Fig-
ure 4 presents the equivalent data for patients from
the 12-week study in CM. In both studies, the mod-
elled data from the two regressions show a closer fit
with the observed values, compared with the Poisson
reference model.
Discussion
This analysis is an assessment of the ability of longi-
tudinal parametric models to capture intra- and
inter-patient variability in MMD frequency over
time, using data from two erenumab clinical trials as
examples. Patients with migraine experience consid-
erable day-to-day variability in the frequency, dur-
ation and severity of attacks [16]. This approach was
used to estimate patient distribution accurately by
the frequency of MMD using mean MMD values for
the overall patient population. Modelling MMD with
negative binomial and beta-binomial longitudinal re-
gression models can be advantageous because they
can accommodate overdispersed data (with a vari-
ance larger than the mean) and account for the vari-
ation in MMD both within and between individual
patients.
The approaches described here allows the distribu-
tion of individual patients by MMD to be modelled
using only the clinical endpoint of the studies - the
mean change from baseline in MMD compared with
placebo at a single time point. The beta-binomial re-
gression method allows restriction of the maximum
successes (i.e. maximum of 28 MDs), whereas the
negative binomial does not. Despite this, the negative
Fig. 1 Estimated and actual MMD distributions in the EM study at weeks 0, 4, 12 and 24
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binomial showed a better goodness of fit to the MD
distributions than beta-binomial. The modelled data
from the negative and beta-binomial regressions
show a closer fit with the observed values, compared
with the Poisson reference model. The zero-inflated
negative binomial regressions did not substantially
improve the goodness of fit of the predicted distri-
butions. In contrast to clinical trial populations that
may have a lower bound of MDs per month, the
zero-inflation model may be more useful in a
real-world population where a greater proportion of
people have zero MDs in a month.
The choice of distributions is important when meas-
uring count data. The Poisson and negative binomial
distributions have been used in previous studies to
model count data [20, 23, 37] and have also been used
to approximate headache day frequency data in pub-
lished migraine studies [17, 38]. However, these distri-
butions may be inappropriate when event counts are
limited by a maximum possible frequency or measur-
ing multimodal distributions. The Poisson and nega-
tive binomial distribution have indefinite support for
positive integers and, therefore, have the potential to
generate inappropriate values, especially with migraine
cohorts of higher MD frequency.
Modelling data as continuous events rather than cate-
gorising data has many advantages, including the reduc-
tion of bias and more accurately estimating the extent of
variation in outcomes between groups [14].This analysis
takes the approach of modelling migraine frequency as a
continuous outcome and addresses a key limitation of
previous modelling approaches which define health
states by categorical event frequency or response status.
The proposed approach also provides a greater capabil-
ity to model indirect comparisons than previous
models, as the published endpoints of clinical studies
(i.e. mean change in MMD) can be used to estimate the
distributions of patients, assuming the patient-level
variation is similar across cohorts. Using a count-based
structure makes indirect comparisons straightforward
because data can be linked to study primary endpoints.
Estimating the distribution of patients by MMD also al-
lows outcomes linked to MD frequency (such as
health-related quality of life or pain medication use) to
be quantified directly as a function of frequency. Fur-
thermore, because clinical trials in migraine are
commonly placebo-controlled, this approach could be
used to parameterise indirect comparison in migraine
prevention where patient-level frequency data are not
available.
Fig. 2 Estimated and actual MMD distributions in the CM study at weeks 0, 4, 8 and 12
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Table 2 EM regression output for negative-binomial, beta-binomial and Poisson
Negative binomial (Dispersion parameter 0.2397) Beta-binomial (ICC 0.0297) Poisson
Covariate Predicted MD
Frequencya
95% CI FRR 95% CI P value Predicted MD
Frequencya
95% CI Coefficient 95% CI P value Predicted MD Frequencya 95% CI FRR 95% CI P value
Week 0 8.261 (7.622,
8.900)
– – – Week 0 7.944 (7.334,
8.555)
– – – Week 0 8.333 (7.790,
8.877)
– – –
Week 4 7.199 (6.714,
7.684)
0.746 (0.712,
0.782)
< 0.001 Week 4 7.081 (6.595,
7.567)
−0.292 (− 0.345,
-0.239)
< 0.001 Week 4 7.312 (6.824,
7.800)
0.768 (0.737,
0.800)
< 0.001
Week 8 6.731 (6.278,
7.185)
0.693 (0.661,
0.727)
< 0.001 Week 8 6.672 (6.215,
7.128)
−0.379 (−0.433,
-0.324)
< 0.001 Week 8 6.847 (6.385,
7.310)
0.718 (0.688,
0.749)
< 0.001
Week 12 6.4337 (6.005,
6.862)
0.651 (0.620,
0.683)
< 0.001 Week 12 6.386 (5.952,
6.820)
−0.447 (−0.503,
-0.391)
< 0.001 Week 12 6.555 (6.108,
7.002)
0.677 (0.649,
0.706)
< 0.001
Week 24 6.421 (6.002,
6.840)
0.634 (0.604,
0.666)
< 0.001 Week 24 6.293 (5.866,
6.720)
−0.486 (−0.542,
-0.429)
< 0.001 Week 24 6.552 (6.105,
6.998)
0.662 (0.634,
0.690)
< 0.001
Treatment (Erenumab vs Placebo) 0.761 (0.702,
0.825)
< 0.001 Treatment (Erenumab vs Placebo) −0.327 (−0.362,
-0.291)
< 0.001 Treatment (Erenumab vs Placebo) 0.764 (0.705,
0.827)
< 0.001
RMSE 0.075 RMSE 0.102 RMSE 0.142
MAE 0.246 MAE 0.336 MAE 0.466
Regression output analysis was based on the whole sample of patients (4438 observations)
CI confidence interval, FRR frequency rate ratio, ICC intraclass correlation coefficient, MAE mean absolute error, MMD monthly migraine day, RMSE root mean squared error
aIn the placebo arm
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Table 3 CM regression output for negative binomial, beta-binomial and Poisson
Negative binomial (Dispersion parameter 0.1323) Beta-binomial (ICC 0.1370) Poisson
Predicted MD
Frequencya
95% CI FRR 95% CI P value Predicted MD
Frequencya
95% CI Coefficient 95% CI P value Predicted MD
Frequencya
95% CI FRR 95% CI P value
Week 0 18.111 17.052,
19.171)
– – – Week 0 17.111 (16.156,
18.066)
– – – Week 0 18.298 (17.373,
19.223)
– – –
Week 4 15.418 (14.579,
16.257)
0.783 (0.754,
0.812)
< 0.001 Week 4 15.843 (15.028,
16.657)
−0.256 (− 0.321,
-0.192)
< 0.001 Week 4 15.577 (14.770,
16.385)
0.798 (0.773,
0.824)
< 0.001
Week 8 14.538 (13.759,
15.317)
0.721 (0.694,
0.749)
< 0.001 Week 8 15.256 (14.484,
16.027)
−0.359 (−0.426,
-0.293)
< 0.001 Week 8 14.688 13.919,
15.457)
0.739 (0.715,
0.764)
< 0.001
Week 12 13.997 (13.242,
14.753)
0.696 (0.670,
0.724)
< 0.001 Week 12 14.894 (14.146,
15.641)
−0.408 (−0.475,
-0.341)
< 0.001 Week 12 14.142 13.397,
14.887)
0.715 (0.692,
0.739)
< 0.001
Treatment (Erenumab vs Placebo) 0.828 (0.767,
0.894)
< 0.001 Treatment (Erenumab vs Placebo) −0.3600 (−0.430,
-0.290)
< 0.001 Treatment (Erenumab vs Placebo) 0.831 (0.770,
0.896)
< 0.001
RSME 0.082 RMSE 0.081 RMSE 0.152
MAE 0.330 MAE 0.339 MAE 0.654
Regression output analysis was based on the whole sample of patients (1872 observations)
CI confidence interval, FRR frequency rate ratio, ICC intraclass correlation coefficients, MAE mean absolute error, MMD monthly migraine day, RMSE root mean squared errors
a In the placebo arm
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While this approach addresses key limitations of
previous approaches, such as defining health states by
categorical event frequency or response status, some
potential improvements could be made to it. The im-
plementation of a negative binomial regression with
upper bound (28 MDs) could be considered and
treatment-visit interactions could be included. Add-
itionally, the data are required to fit to the smooth
distributions of the model; however, this is not always
the case. The predicted distributions observed in the
CM study did not fit as well as the EM study owing
to the greater spread in distribution in the CM study
and may also be due to the differences in the patient
populations between the EM and CM cohorts. There-
fore, alternative approaches may be required to better
model these cohorts.
The method described here has applications in eco-
nomic evaluations of preventative medication and pol-
icy decisions in migraine. The parametric approach
proposed can be used to perform extrapolations of
treatment effects beyond trial observations. Extrapola-
tion of data is particularly relevant when considering
economic evaluations [39] as patient-level data col-
lected within the duration of clinical studies are often
too short to assess the long-term relationship between
migraine frequency and health status. Further research
may consider how such data should be extrapolated
into the future, as whilst survival-modelled extrapola-
tion has become well-established and standardised,
the parametric approach is relatively novel, and the
way in which the data can be best extrapolated is yet
to be defined [40]. Furthermore, there is an inherent
risk to extrapolation, as the clinical trajectory can be
uncertain.
Modelling outcomes as continuous variables rather
than health states has advantages when data are lim-
ited. Therefore, this approach has implications for use
in various disease analyses which have simplified con-
tinuous outcomes associated with health states, which
may result in loss of information or bias. This ap-
proach could be used to evaluate the disease progres-
sion of patients with HIV/AIDS, where multistate
Markov models based on CD4 cell counts have previ-
ously been used [41] or modelling health assessment
questionnaire (HAQ) scores in patients with psoriatic
arthritis [42].
Conclusions
Modelling MMD with regression models that can ac-
commodate overdispersion in a longitudinal framework
is a statistically valid method to estimate the variation in
MMD, both within and between individual patients. This
approach, which estimates the distribution of patients by
MMD, allows outcomes (such as health-related quality
of life or pain medication use) to be directly quantified
and linked to MD frequency. This has important appli-
cations in the evaluation of preventive medications for
migraine and beyond.
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Additional file 1: Table S1. EM and CM regression output for zero-
inflated negative binomial. Contains the data for the EM and CM regression
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Additional file 3: Figure S2. Mean MD extrapolations based on
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MMD are based on the predicted means produced by the beta-
binomial and negative binomial regression models of both EM and
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Additional file 4: Implementation of regression models in Stata. The
technical appendix contains the Stata codes which were used to fit the
regression models. (DOCX 13 kb)
Fig. 3 MMDs over 24weeks of the EM study: negative binomial and
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beta-binomial longitudinal regression estimates and observed data.
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binomials indicated by the shaded grey (placebo) and red (erenumab)
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